Members of the nuclear receptor (NR) superfamily regulate both physiological and pathophysiological processes ranging from development and metabolism 1 to inflammation 2 and cancer 3 . As ligand-gated transcription factors, synthetic small molecules targeting NRs are often deployed as therapeutics to correct aberrant NR signaling or as chemical probes to explore the role of the receptor in physiology 4 . However, nearly half of NRs do not have specific cognate ligands or its unclear if they possess ligand dependent activities and these receptors are called orphans. Here we demonstrate that ligand-dependent action of the orphan nuclear receptor RORγ can be defined by selectively disrupting putative endogenous-but not synthetic-ligand binding. Furthermore, the characterization of a library of RORγ modulators reveals that structural dynamics of the receptor assessed by HDX-MS correlate with activity in biochemical and cell-based assays. These findings are corroborated with X-ray co-crystallography and sitedirected mutagenesis to collectively reveal the structural determinants of RORγ liganddependent activation, critical for designing full agonists for application in cancer immunotherapy.
INTRODUCTION
RAR-Related Orphan Receptor C (RORγ, gene name RORC) is an orphan nuclear receptor that is widely expressed and is involved in regulation of various metabolic processes 1, 5 .
RORγ is also a key player in the immune system where the lymphocyte specific isoform RORγt is a so-called 'master regulator' of the IL-17 producing T helper (Th17) cell subset 6 . Human patients with nonsense mutations are susceptible to candida infection of the lung 7 , suggesting that the evolutionary pressure of RORγ weighs heavily on immune function. The development of ligands that repress RORγt action have been extensively pursued to treat Th17-mediated autoimmune disorders such as multiple sclerosis and psoriasis 8, 9 . More recently, RORγ has also been found to be the driver of the androgen receptor in metastatic castration resistant prostate cancer where the selective RORγ antagonist SR2211 elicits a potent cytostatic effect 10 .
Conversely, ligands that activate RORγt have been implicated in improving Th17-mediated protective antitumor immunity 8, 9 but comparatively, their development has lagged.
While activating ligands of RORγt are present during T cell maturation 11 , synthetic RORγ agonists have been found to further activate the receptor (hyperactivation) 12, 13 . Overexpression of RORγt is sufficient to induce IL-17 expression in Naïve CD4+ T cells 6 although it is unclear if this activity is ligand dependent, or if it can be increased further with synthetic agonists.
Interestingly, our lab and others have demonstrated that RORγ agonists not only increase expression of IL-17 expression, but also decrease levels of programmed cell death 1 receptor (PD-1) 12, 14 . T cell surface PD-1 interaction with PD-L1 presented on tumor cell surfaces deactivates cytotoxic T cell responses and promotes regulatory T cell phenotypes in CD4+ subsets. Therapies targeting PD-1 have been very successful in improving immune surveillance of tumors in the context of non-small cell lung cancer, metastatic melanoma, and renal cell carcinoma 15 . Indeed, chimeric antigen receptor expressing T cells treated with RORγ agonists potentiate tumor clearance activity in mouse models 14 . These findings further implicate RORγ agonism as a potential therapeutic strategy not only to enhance protective anti-tumor immunity by increasing IL-17 expression but also attenuating immunosuppressive action through PD-1 stimulation with one compound in clinical development for cancer therapy 14, 16 . Recently, we developed a series of N-arylsulfonyl indoline orthosteric RORγ agonists that were optimized for potency and selectivity 17 .
Structural and functional analysis has revealed that the RORγ ligand binding domain (RORγLBD) is comprised of 12 α-helices (H1-H12) and a β-sheet region (BSR) that responds to cholesterol biosynthetic pathway intermediates, hydroxysterols and sterol sulfates 11, 18, 19 . While the intrinsic activity of the receptor has been presumed to be ligand-dependent, recent studies have called to question the basis of the receptor's activity in situ. These studies include the crystal structure and NMR solution of 'apo' RORγ 20 , and recent molecular dynamic simulations 21, 22 . Collectively, these studies have identified that the gauche rotomeric state of W317 stabilizes H11, H11' and H12 through extensive hydrophobic interaction networks formed with F486, F506, Y502, and H479 as the key drivers of RORγ hyperactivation by stabilizing the required Y502-H479 hydrogen bond. Herein, we explore the ligand-dependent activities of the RORγLBD using site-directed mutagenesis. We further explore the structural basis for ligandmediated hyperactivation of the RORγLBD using a comprehensive structural characterization by hydrogen-deuterium exchange coupled with mass spectrometry (HDX-MS) and RORγ LBD: ligand co-crystal structures. The results presented here indicate that the RORγLBD requires a ligand to stabilize the active conformer and that hyperactivating ligands enhance coactivator affinities by allosterically driving electrostatic intramolecular interactions between H12 and H4.
Combined these observations are explained by a revised model of RORγ activation which is used to more accurately describe RORγ pharmacology. In the presence of endogenous ligands or partial agonists, such as 25-hydroxycholesterol (25OHC) or SR19265, several regions of RORγ became protected to solvent exchange with the most dramatic being the BSR and H12 (Figure 1F and 1G) . Other regions that constituted the orthosteric binding site, but also distal regions including H1 and H9, exhibited significant protected to exchange. HDX-MS analysis of the selective RORγ inverse agonist SR2211 revealed a distinctive profile. Specifically, RORγLBD bound to SR2211 exhibited protection to amides surrounding the orthosteric binding site, but SR2211 offered no protection to H12 suggesting that the activation function surface remains disordered. The co-crystal structure solution of the RORγLBD bound to SR2211 reveals a deactivation where the carbinol moiety pushes W317 into an alternative conformation that prevent H11' and H12 from nucleating.
RESULTS

HDX-MS characterization of
These findings are consistent with previously observed pharmacology 23 and show that HDX-MS measurements can distinguish agonists from inverse agonists. To examine responses to coactivator peptides, Differential HDX-MS was performed using the binary RORγLBD:SR19265 complex treated with a synthetic peptide derived from steroid receptor coactivator 1 NR-box 2 (SRC1-2) or Tris-EDTA buffer (vehicle). The presence of SRC1-2 resulted in further protection to H4 and H10-12 consistent with published co-crystal structure solutions with coactivator peptides indicating ternary complex formation 18 , Sup Fig 1B. SRC1-2 was also able to protect these regions of the protein in the absence of SR19265 albeit to much lesser degree. Overall, the findings of these studies demonstrate the tractability between the structure of the protein and solution phase dynamics determined with HDX-MS. We also compared the dynamics of the RORγLBD-SRC2 fusion construct (RORγ265-507-GGG-SRC2-2), which was used to solve the 'apo' RORγ crystal structure, with our RORγLBD construct. This construct demonstrated similar kinetics of the ternary complex suggesting that the fusion construct artificially stabilizes the active conformer in solution, Sup Fig 1C and 1E . Overall, this system exhibited behavior that was consistent with previous studies. (red) and 25-hydroxycholesterol (blue, 25-OHC) are compared. Both compounds are shown in the context of co-crystal structure solutions with RORγ (PDB 3L0L) where helices 5, 6 and 7 (H5, H6, and H7) as well as the beta sheet region (BSR) are shown. SR19265 and 25hydroxycholesterol are shown in red and blue respectively. A368V was found to be a mutation that selectively disrupts endogenous ligand binding presumably through steric clashes. WT and A368V RORγLBD were tested in an AlphaScreen-based SRC1-2 coactivator peptide recruitment assay in panels B and C, respectively. on coactivator recruitment D) HEK293T cells were transiently transfected with a vector encoding full length RORγ and a 5xRORE-luciferase reporter.
The WT and A368V variant were tested for their baseline activity as well as their response to 
RORγ is not constitutively active. The RORγ modulator SR19265 was characterized using an
AlphaScreen-based coactivator peptide interaction assay and a cell-based promotor reporter assay. SR19265 was able to interact with a synthetic peptide derived from SRC1 NR-box 2 (SRC1-2) with similar potency and fold activation of the reported endogenous agonists 25hydroxycholesterol (25OHC) and desmosterol ( Figure 1B) . In cell-based assays, SR19265 was able to increase activity of a luciferase reporter above the baseline in cell-based assays Figure   1D . However, SR19265 exhibited a marked reduction in potency and the differences in activity were non-significantly different from the DMSO treated control group at a 1 uM dose compared to biochemical assays, Figure 1E . Examination of the co-crystal structure of RORγLBD bound to SR19265 revealed a distinct binding pose compared to a representative hydroxycholesterol 25OHC, Figure 1A . While 3-hydroxy and 3-sulfocholesterols are thought to be stabilized by hydrophobic contacts and hydrogen bonds with R367 18 , SR19265 binding was located further away from R367 and the interaction is driven strictly through hydrophobic contacts. Importantly, hydrophobic interactions observed by both compounds with BSR amino acids, F378 and F388, help explain dramatic protections to deuterium exchange to the β-sheet region (BSR) observed by HDX-MS. SR19265 makes hydrophobic contacts with W317 and H479 thereby stabilizing H10 and H12 through the W317-F486 π stack and H479-Y502 hydrogen bond respectively, Figure 2A . To explain the observed differences in functional assays we tested both RORγ activation models (constitutive activity and activation by endogenous agonists) using sitedirected mutagenesis. We hypothesized that a simple mutation to A368 could selectively disrupt hydroxycholesterol binding but not SR19265 binding. Using the SRC1-2 coactivator peptide interaction assay, we observed a marked reduction in hydroxycholesterol-mediated activation of A368V RORγLBD while SR19265 retained potency compared to the WT variant. In the cellbased promotor reporter assay, the A368V mutation is a loss of function where activity is recoverable with synthetic modulator, Figure 1D . The A368V mutant showed marked reduction in basal activity and exhibited a more potent response to SR19265. The presence of 1 μM SR19265 was able to recover activity to that of the WT receptor, Figure 1E . A possible explanation to the observed loss of function due to mutation of A368 to valine is that the valine residue disrupts the structural dynamics of the LBD. To test this hypothesis, we employed differential HDX-MS to examine changes in structural dynamics between A368V and WT RORγLBD, as well as the ligand dependent perturbations to SR19265 and 25OHC, Figure 1F through 1I. Compared to WT RORγLBD, the A368V mutant showed faster solvent exchange in the BSR, H1, and H3. In the presence of 25OHC, the solvent exchange of these regions was reduced to levels similar to WT treated with vehicle and there was no stability introduced to H12, Figure 1C . On the other hand, A368V RORγLBD treated with SR19265, Figure 1H , showed similar protection to exchange as the WT RORγLBD treated with SR19265, Figure 1F , suggesting that the A368V variant liganded with SR19265 maintained similar structural dynamics to the WT receptor bound to SR19265. SR19547 and SR19355 are a full agonist and an antagonist respectively. To test this model, we began characterizing representatives of N-aryl sulfindoline (shown in Figure 2A ) class of RORγ modulators using co-crystallography, in vitro functional assays, and HDX-MS 17 . In a fluorescence polarization-based coactivator peptide interaction assay, SR19265 and SR19547 treatment enhances the EC50 of RORγLBD association with SRC1-2 to 12 μM and 1 μM respectively compared to 53 μM for the DMSO treated protein control, Figure 2E . The enhanced affinity for coactivator is consistent with the cell-based assays results where SR19547 is able to hyperactivate RORγ about 50-80% above the basal level, Figure 2F . Both SR19265 and SR19355 co-crystal structures were solved with 2.7 and 2.3 Å resolution respectively, Sup Table 1 and Sup Figure 2B -2C. In general, SR19265 and SR19355 share similar binding poses within the ligand binding pocket and make general hydrophobic contacts through the indoline and substituted benzoyl moieties with H3, H7 and H10 where protection to HDX is also observed Figure 2B and 2C. Interestingly, the amide of SR19355 acts as a H-bond donor for H479, which disrupts the H479-Y502 H-bond leading to destabilization of H12. This finding is corroborated by HDX-MS where SR19265 treatment protects H12, whereas SR19355 treatment does not protect H12 to solvent exchange. As expected, SR19355 treatment further reduces coactivator peptide interaction, and like SR2211, SR19355 also robustly reduced RORγ activity in cells, Figure 2F . These results are consistent with previous analysis with SR2211 23 . After obtaining co-crystal structures of partial agonist SR19265 and antagonist SR19355, we attempted and failed to solve co-crystal structures of full agonist SR19547 bound to the RORγLBD. Despite this, we were still able to study the effects of SR19547 on the dynamics of the RORγLBD where we see protection to H3, the BSR, with stronger protection to H12, Figure   2C and 2D, indicating that SR19547 strongly stabilizes the active conformation of RORγ. This finding supports a model where SR19547 increases coactivator affinity by presumably reducing entropic penalties of binding. for 38 compounds with 5 replicates. All compounds were found to generally engage the receptor in the orthosteric ligand binding pocket based on observed protection to H3-H7 and the BSR.
The collection of ligands showed a wide range of deuterium exchange protection within H12.
Compounds generally clustered into 3 groups; the first included compounds that did not stabilize H12 (likely antagonists or inverse agonists), the second group consisted of partial agonists that weakly stabilize H12, and the constituents of the third group strongly stabilized H12.
Before performing the covariation analysis, we first removed peptides with perturbation values that were not significantly different (false discovery rate < 0.05) from the DMSO treated control after applying a Benjamani-Hochberg multiple test correction. This filtered 108 peptidetimepoints combinations to 29 peptides-timepoints that are shown in Figure 3A . Using this shorter list of peptides, we performed a covariation analysis to look for correlation between activity in functional assays. As expected, we observed that H12 stability at the 10 second timepoint correlated (R 2 = 0.638) with the ligand-dependent recruitment of SRC1-2, Figure 3E .
We also observed that perturbation values of H4 at the 4 hour timepoint correlated (R 2 = 0.476) with coactivator recruitment activity, Figure 3B . Furthermore, protection to deuterium exchange in H2, H3, H7, the BSR, and H10 also correlated with coactivator peptide activity, Figure 3D .
Linear regression between perturbation values of several H1 peptides and AlphaScreen activity were found to have correlation coefficients that were significantly different from zero (adjusted P value < 0.01) but were non-predictive (R 2 < 0.5). Overall, these measurements indicated some relationship between dynamics of these regions with activation of RORγ in vitro. In general, ligand dependent thermal stabilities and perturbation values showed weaker correlation. While perturbation values of peptides from four regions (H2, H3, the BSR, and H7, Figure 3G ) were found to have with significantly nonzero correlation coefficients in a linear model, only protection to the BSR showed predictive correlation (R 2 = 0.538), Figure 3H . Importantly, SR19355 displayed much higher performance in this assay with no commensurate increase in protection at these regions. This highlights an important limitation to the approach where differences in binding mode (an additional hydrogen bond in this case) can identify compounds as outliers.
The linear models describing thermal stability as the predicted value only described distributions that exclude SR19355. Next, we sought to correlate the biophysical measurements with activity of compounds in a cell-based promotor-reporter assay. The compounds were tested in a GAL4-RORγLBD co-transfection format using UAS-luciferase as a reporter gene. Cells were treated with 2 uM ursolic acid to repress the activity of RORγ prior to addition of test compounds, and activity of compounds were presented as fold change over DMSO only control. The activity in such an assay for the compound collection has already been reported as fold change in luciferase activity compared to DMSO treated control 17 . Compounds afforded similar patterns to the peptide coactivator recruitment assay, but correlation trends were somewhat different.
Perturbation values of peptides originating in H2, H3, the BSR, H7, and H12 were found to have significantly nonzero correlation coefficients, Figure 3J . Interestingly, protection to H12 became a less significant predictor (R 2 = 0.392) of activity within cells, Figure 3F . Instead, activity in cellbased assays was best predicted by protection to H2 (R 2 = 0.512) and H7 (R 2 = 0.496), Figure   3C and 3I. Compounds that protected these regions to deuterium exchange typically had a higher fold change in reporter gene activity compared to cells treated only with DMSO. To assess if regions of the protein have concerted motions, we performed an analysis of covariation to look for peptides within the LBD that have percent deuterium incorporation of equal magnitude, Sup Fig 4. The correlation coefficient (R 2 ) is plotted as a heatmap in Figure   4A . Peptides with overlapping sequences typically correlated with each other. We found that ligand-dependent perturbation values clustered into three groups, Figure 4B . The first group correlated with H12 and consisted of H1, H4 and H10. While most compounds protected H12, SR19269 and SR19355 exhibited little protection to this region. This helped to determine whether the correlations were coincidental, or dependent on H12 stability. Since SR19355 and SR19269 were clear outliers in the H12-H1 correlation plot, Figure 4D , this correlation was likely coincidental where H1 happens to be more stable when H12 is stable. However, SR19355 and SR19269 also exhibit commensurate H4 protection showing that the observed H4 stability depends on H12 stability. Furthermore, a correlation coefficient of 0.779 suggests that a simple linear model explains most of the variance of the distribution, Figure 4C . The second cluster were correlated strongly (R 2 > 0.7) with the BSR and consisted of H3 and H7. SR19269 and SR19355 did not appear to be obvious outliers with the second group. This region is likely where compounds were directly engaging the protein, so it is unclear that the stabilities of the region depended on each other or were simply driven by varying degrees of ligand binding. The third group consisted of a single peptide from H2, shown in green in Figure 4B , which correlated with both H12 and the BSR. Perturbation values of this peptide correlated strongly peptides from the BSR (R 2 = 0.698), Figure 4H . Given that SR19269 and SR19355 were clear outliers, the correlation with H12 appeared to be coincidental, Figure 4E . A network of electrostatic interactions is required to activate RORγ. Given the correlation with activation in vitro, we sought to further explore the relationship of H12 and H4 dynamics. To do this, we identified candidate intramolecular interactions formed by K354 and K503 by examining the structure. Both residues are hydrogen bond donors to backbone carbonyl as depicted in Figure 5A . Using site directed mutagenesis in combination with functional assays and HDX-MS, we characterized alanine and arginine mutants at both sites to study the role of the residues in receptor activation. Introducing either K503A or K354A variations to a GAL4-RORγLBD resulted in a loss of function in cell-based assays, Figure 5B . Mutation to K503R, but not K354R, was able to retain activity similar to WT levels, indicating general electrostatic interactions at K503 but not K354 are sufficient for activation. Treatment with synthetic agonist SR19547 was able to recover activity of the K503A construct, but not the K354A mutant suggesting the H12-H4 interaction is essential to activate RORγ in situ. These findings are reflected with in vitro coactivator interaction assays where K503A and K354A are less active than the WT control in the presence of 25OHC, shown in Figure 5D , respectively. Treatment with synthetic agonist SR19265 was able to recover some activity of the K503A construct and K354A at high concentrations suggesting the interaction between H12 and H4 is essential to activate RORγ in situ, while intramolecular K503 interaction is only required for activation by endogenous ligands. To further evaluate the structure-based model, we employed HDX-MS to examine the changes in solvent exchange due to loss of function mutations K354A and K503A, 
DISCUSSION
To develop RORγ agonism as a therapeutic strategy, we have better characterized the basis of the high basal activity of RORγ and the structural basis of RORγ activation. The data presented here show that A368V RORγ does not respond to endogenous ligand and has little to no intrinsic activity. However, A368V RORγ can be activated by synthetic ligands that can bind the mutant construct. Therefore, endogenous ligands are required for the observed activity in cells, Figure 6B . According to this model, RORγ agonists must not only out compete endogenous ligands, but also stabilize a conformer that is more productive in driving association with coactivators than the endogenous agonists in order to hyperactivate the receptor.
Modulators that activate RORγ to the same level should be considered silent agonists. Based on this model, a more accurate depiction of unliganded RORγ is a dynamic ensemble of conformations, Figure 6A . Experiments reported here show that the SRC2 fusion construct used to solve the 'apo' crystal structure artificially locks RORγ in the active conformation.
Interestingly, SRC2 fusion to H12 mimics ligand-dependent stability around the distal orthosteric binding site and specifically, in the BSR despite being 5 nm away. In addition, the use of mutagenesis to selectively disrupt H10-12, but not the orthosteric binding site suggests that several intramolecular interactions are required to stabilize AF2. Taken together, these observations are consistent with a two-phase activation scheme where ligand recognition through the BSR is required to stabilize the receptor and allow for H10-12 to sample the active conformer. Here we report results from a 'bump-and-hole' strategy that support a model where RORγ has low intrinsic activity in the absence of a small molecule. In light of this, RORγ modulators that drive coactivator interaction, but do not increase RORγ activity above the basal level are silent agonists. While H12 is ordered in the crystal structure solved with coactivator both with and without ligand, H12 behaves as a disordered peptide in solution based on solvent exchange kinetics. Introducing mutations that disrupt endogenous ligand binding result in a loss of function. The results presented here suggest that ligand recognition could originate at the BSR and H3 interface. Not only did every modulator stabilize these regions, but the stability of H3 and the BSR correlated with ligand-dependent stability of the receptor. Furthermore, the experiments done here show that the SRC2 fusion construct used to solve the 'apo' crystal structure artificially lock RORγ in the active conformer. A more accurate representation of apo RORγ is likely a dynamic ensemble where the active conformer likely does not exist for extended periods of time within the cell.
Nuclear receptor structure-activity relationship studies seek to evaluate modulator activity as a function of compound structure. While these studies reveal interesting trends in small molecule development, they fail to explain how the compounds modulate the activities of the receptor. Here we demonstrate that ligand-dependent conformational changes, assessed with HDX-MS, can empirically correlate with functional assay activity to reveal structural determinants for various biochemical activities. The N-arylsulfonyl indoline class of RORγ modulators exhibit disparate activities in biochemical and cell-based assays. The disparity between activation of RORγ in vitro and in cells was evident by the strength of the correlations for different regions of the protein. Ligand-dependent activation of the receptor in vitro and in cells both correlated with H12 stability. Interestingly, stability of H2 was the best predictor of activity in cells. This is likely due to several biochemical activities required to hyperactivate the receptor in cellulo. As H2 stability generally correlated with H3, the BSR, H7 and H12, it is likely that stability of this region of the protein could serve as general indicator of global stability and activation potential.
Materials and methods
Chemicals, Cloning, and Mutagenesis.
Unless otherwise specified, all chemicals and reagents were purchase from Sigma-Aldrich (St.
Louis, MO). Complementary DNA coding for residues 265-518 from human RORγ Variant 1 (Uniprot ID P51449) were cloned into the pESUMO vector using BsaI and XhoI. Mutant constructs were generated using a site-directed mutagenesis kit (Q5, New England Biolabs) using primers described in the supplement. Our RORγLBD-SRC2 cDNA was designed based on a previously published construct 20 , synthesized by Genscript, and cloned into the pESUMO vector using BsaI and XhoI (New England Biolabs). RORγHinge-LBD was cloned into the pBIND vector as previously described 24 . All plasmids were sequence verified.
Protein expression and purification.
All protein constructs were expressed in the E. coli strain BL21 Codon plus (DE3) RIL (invitrogen) cell line. The wild type and variant protein constructs were expressed by culturing E. coli in terrific broth in a temperature controlled orbital shaker (Innova) operating at 200 RPM at 37°C. After the culture reach an optical density (OD610) of 0.5, the temperature of the incubation chamber was dropped to 16°C and IPTG was added to 250 μM. The cultures were then incubated for 16 hours until being harvested by centrifugation at 4°C. Cell pellets were then resuspended in ice cold phosphate buffered saline containing protease inhibitors (EDTA-free SigmaFast, Sigma-Aldrich) prior to subsequent harvesting, flash freezing in liquid nitrogen and storage at -80°C. Unless otherwise mentioned, all protein purification steps were conducted at 4°C. Cell pellets were resuspended with NiNTA buffer A (50 mM Tris pH 8.0, 500 mM NaCl, 10% (v/v) glycerol, and 25 mM imidazole) supplemented with protease inhibitors, DNase, and lysozyme. Cells were lysed using a French press operating at 20,000 psi. The crude cell lysate was clarified by centrifugation (40,000 rcf for 30 minutes) and the supernatant was filtered at 0.2 um prior to loading onto NiNTA resin pre-equilibrated with buffer A using an AKTA protein Table 1 ). Datasets were processed using autoPROC using XDS as the data-processing engine 25 Peptide Identification: Protein samples were injected for inline pepsin digestion and the resulting peptides were identified using tandem MS (MS/MS) with an Orbitrap mass spectrometer (Fusion Lumos, ThermoFisher). Following digestion, peptides were desalted on a C8 trap column and separated on a 1 hour linear gradient of 5-40% B (A is 0.3% formic acid and B is 0.3% formic acid 95% CH3CN). Product ion spectra were acquired in data-dependent mode with a one second duty cycle such that the most abundant ions selected for the product ion analysis by higher-energy collisional dissociation between survey scan events occurring once per second.
Following MS2 acquisition, the precursor ion was excluded for 16 seconds. The resulting MS/MS data files were submitted to Mascot (Matrix Science) for peptide identification. Peptides included in the HDX analysis peptide set had a MASCOT score greater than 20 and the MS/MS spectra were verified by manual inspection. The MASCOT search was repeated against a decoy (reverse) sequence and ambiguous identifications were ruled out and not included in the HDX peptide set.
HDX-MS analysis: For differential HDX, RORγLBD -ligand complexes was formed by incubating RORγLBD (5 µM) with compounds (50 µM) for 1 hour on ice. Next, 5 µl of sample was diluted into 20 µl D2O buffer (50 mM sodium phosphate pH 7.4, 150 mM NaCl, 2 mM TCEP) and incubated for various time points (0, 10, 30, 110, 380, 1270, 4270, and 14400 seconds) at 4°C. The deuterium exchange was then slowed by mixing with 25µl of cold (4°C) 3M urea and 1% trifluoroacetic acid. Quenched samples were immediately injected into the HDX platform. Upon injection, samples were passed through an immobilized pepsin column (2mm × 2cm) at 50µl min −1 and the digested peptides were captured on a 2mm × 1cm C8 trap column (Agilent) and desalted. Peptides were separated across a 2.1mm × 5cm C18 column (1.9 µl Hypersil Gold, ThermoFisher) with a linear gradient of 4% -40% CH3CN and 0.3% formic acid, over 5 minutes. Sample handling, protein digestion and peptide separation were conducted at 4°C. Mass spectrometric data were acquired using an Orbitrap mass spectrometer (Fusion Lumos, ThermoFisher). The intensity weighted mean m/z centroid value of each peptide envelope was calculated and subsequently converted into a percentage of deuterium incorporation. This is accomplished determining the observed averages of the undeuterated and fully deuterated spectra and using the conventional formula described elsewhere 30 . Corrections for back-exchange were determined empirically using a Dmax control. Briefly, this sample was generated by mixing 5 μL of protein sample with 20 μL of deuterated buffer and incubated at 37°C overnight before being queued to for subsequent quenching, and injection.
Data Rendering: The HDX data from all overlapping peptides were consolidated to individual amino acid values using a residue averaging approach. Briefly, for each residue, the deuterium incorporation values and peptide lengths from all overlapping peptides were assembled. A weighting function was applied in which shorter peptides were weighted more heavily and longer peptides were weighted less. Each of the weighted deuterium incorporation values were then averaged to produce a single value for each amino acid. The initial two residues of each peptide, as well as prolines, were omitted from the calculations. This approach is similar to that previously described 31 . HDX analyses were performed in triplicate, with single preparations of each purified protein/complex. Statistical significance for the differential HDX data is determined by t-test for each time point and is integrated into the HDX Workbench software 32 .
Thermal Shift Assay
Differential Scanning Fluorimetry based thermal shift assays were conducted using GloMelt 
Coactivator recruitment Assays
AlphaScreen: AlphaScreen-based peptide recruitments assays were performed using streptavidin coated donor beads and anti-His-tag antibody coated AlphaLisa acceptor beads (Perkin Elmer). The assays were very sensitive to the distance of the N-terminus to the LXXLL NR-box motif and the use of a flexible Ahx linker. Briefly, 10 μL of a 100 nM HisSUMO-RORγLBD in assay buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 5 mM DTT, 0.01% NP40) were plated in a black 384 well low-volume plate (Greiner). 100 nL of 200X compound or vehicle control solutions were added using a BioMeck NX p pintool, 5 μL of a 200 nM Biotin-Ahx-SRC1-2 was added and the 15 μL solution was incubated at room temperature for 30 minutes, after which, 5 μL of 4X bead cocktail was added. The bead slurry was incubated at RT for 30 minutes before reading on an EnVision plate reader (Perkin Elmer).
Fluorescence polarization: Fluorescence polarization-based peptide recruitment assays were performed in 20 μL reaction volumes in low volume 384 well plates offered by Greiner.
Fluorescent peptides were labeled at the N-terminus with FITC (Lifetein). Briefly, 10 μL of 2x protein (180 -0 μM) solution in assay buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 5 mM DTT, 0.01% NP40) were added to a black 384 well plate (Greiner). 4x compound solutions were made by diluting a 10 mM stock in DMSO into assay buffer and added to a final concentration of 100 μM. After a 15 minute incubation period at room temperature, FITC-SRC1-2 was added to 100 nM in a 5 μL 4x solution in assay buffer. Fluorescence polarization was read on a
Cell-based promoter-reporter assays
The pBIND-RORγHinge-LBD plasmid was cotransfected with UAS-LUC and TK-LUC plasmids into HEK293T cells using extremeGene transfection regeant. After overnight incubation, cells were seeded into 96 well plates and compounds or vehicle controls were added 6 hours later.
Dual luciferase assays were performed using Dual-Glo firefly and renilla luciferase reagents according to the manufacturers protocol. Results were analyzed using GraphPad Prism software. Twenty-four hours after treatment, the luciferase activity was measured using the
Statistical treatments and analysis
Unless specified otherwise, all biochemical and cell-based assays were performed with triplicate technical replicates and at least 2 biological replicates. Fluorescence polarization assays were performed with 2 technical replicates per condition. While full time course HDX-MS was conducted with 3 technical replicates, 2 time point HDX-MS screening of RORγ modulators was done with 6 technical replicates per compound and repeated on a separate batch of protein. To perform the correlation and covariation analysis, R version 3.5.0 was used to analyze a collection of HDX-Workbench outputs from 38 modulator differential experiments. After extracting perturbation values (Δ%D) for 54 peptides at two timepoints for 38 compounds, a 2 tailed t test was applied to determine likelihood that the values were significantly different from 0. After applying a Benjamini-Hochberg multiple test correction 33 , only peptide-timepoints combinations where 15 or more compounds had perturbation values significantly different from 0 (false discovery rate < 0.05) were kept. Using this reduced dataset, a Pearson correlation analysis comparing perturbation values to functional assay activity values was conducted using the Psych package. Again, the multiple test correction method of Benjamini-Hochberg was applied and the resulting adjusted p values and R 2 were visualized in excel. Selected correlations were manually charted in GraphPad Prism 5. The PerformanceAnalytics package (ref needed) was used to generate plots to visualize covariation within the reduced HDX-MS data set. The correlogram was generated using the corrplot package in a way that only showed R 2 values whose corresponding covariation adjusted p values was less than 0.01. Selected covariation plots were manually generated in GraphPad Prism 5.
